HNRNPR Gene

Migration, Crosslink

📖

HNRNPR Gene

active

wiki page Created: 2026-04-02T07:19:28 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-hnrnpr

📖 Wiki Page

gene2880 wordssynced 2026-04-02

HNRNPR (Heterogeneous Nuclear Ribonucleoprotein R)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HNRNPR Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>HNRNPR</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>HNRNPR</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=HNRNPR" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Introduction

HNRNPR (Heterogeneous Nuclear Ribonucleoprotein R) is a gene located on chromosome 1p36.22 that encodes an RNA-binding protein belonging to the heterogeneous nuclear ribonucleoprotein (hnRNP) family. This gene plays critical roles in post-transcriptional gene regulation, including pre-mRNA processing, alternative splicing, mRNA stability, and RNA transport. HNRNPR is expressed throughout the central nervous system and has been increasingly recognized for its involvement in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease[@kim2019].

...

HNRNPR (Heterogeneous Nuclear Ribonucleoprotein R)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HNRNPR Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>HNRNPR</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>HNRNPR</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=HNRNPR" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Introduction

HNRNPR (Heterogeneous Nuclear Ribonucleoprotein R) is a gene located on chromosome 1p36.22 that encodes an RNA-binding protein belonging to the heterogeneous nuclear ribonucleoprotein (hnRNP) family. This gene plays critical roles in post-transcriptional gene regulation, including pre-mRNA processing, alternative splicing, mRNA stability, and RNA transport. HNRNPR is expressed throughout the central nervous system and has been increasingly recognized for its involvement in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease[@kim2019].

The HNRNPR protein contains multiple RNA recognition motifs (RRMs) that enable it to bind to specific RNA sequences and participate in various aspects of RNA metabolism. Dysregulation of HNRNPR has been linked to altered RNA metabolism observed in neurodegenerative conditions, making it a subject of significant interest in understanding the molecular mechanisms of neuronal death and exploring potential therapeutic targets[@dawson2019].

Gene Structure and Protein Architecture

Genomic Location and Organization

The HNRNPR gene spans approximately 18.5 kilobases on the short arm of chromosome 1 (1p36.22), a region that has been implicated in various neurological disorders. The gene consists of 15 exons that undergo alternative splicing to generate multiple transcript variants. The gene promoter contains regulatory elements that respond to neuronal activity and stress conditions, allowing dynamic regulation of HNRNPR expression in different physiological and pathological contexts.

Protein Domain Structure

The HNRNPR protein is approximately 644 amino acids in length with a molecular weight of around 70 kDa. The protein architecture includes:

N-terminal region: Contains a prion-like domain with low complexity sequences that mediate protein-protein interactions
RNA Recognition Motifs (RRMs): Four RRMs (RRM1-4) in the central and C-terminal regions that provide RNA binding specificity
C-terminal glycine-rich region: Involved in protein-protein interactions and nuclear localization

The RRMs of HNRNPR exhibit distinct binding preferences for different RNA sequence elements. RRM1 and RRM2 primarily recognize pyrimidine-rich sequences, while RRM3 and RRM4 show preference for specific secondary structures. This diverse RNA binding capability allows HNRNPR to participate in multiple RNA processing events within neurons[@ray2013].

Biological Functions in Neurons

Pre-mRNA Processing and Alternative Splicing

HNRNPR plays a central role in the regulation of alternative splicing, a critical mechanism for generating protein diversity in neuronal cells. The protein interacts with components of the spliceosome machinery and modulates the inclusion or exclusion of specific exons in target transcripts. In neurons, HNRNPR-regulated splicing events are particularly important for:

Synaptic protein isoforms: Regulation of splice variants for receptors, ion channels, and scaffolding proteins
Cytoskeletal proteins: Alternative splicing of tau and microtubule-associated proteins
Apoptotic regulators: Splicing of Bcl-x, caspase-9, and other cell death-related transcripts

Studies have shown that HNRNPR participates in the splicing of survival motor neuron (SMN) transcripts, which is particularly relevant to ALS pathogenesis[@bannerman2015]. The SMN protein is essential for spliceosome assembly, and dysregulation of this pathway contributes to RNA processing deficits observed in motor neuron disease.

mRNA Stability and Turnover

Beyond splicing, HNRNPR regulates mRNA stability by binding to specific elements in the 3' untranslated regions (UTRs) of target mRNAs. The protein can either stabilize or destabilize transcripts depending on the specific RNA binding partners and cellular context. This function is particularly important for:

Rapid response genes: Immediate-early genes and stress-responsive transcripts
Synaptic plasticity mediators: CaMKII, Arc, and other activity-regulated transcripts
Neurotrophic factors: BDNF and other survival-promoting mRNAs

The regulation of mRNA stability by HNRNPR allows neurons to fine-tune protein expression in response to synaptic activity, stress, and pathological stimuli. Alterations in this regulatory capacity contribute to the synaptic dysfunction observed in neurodegenerative diseases.

RNA Transport and Local Translation

Neurons rely on localized RNA translation for synaptic plasticity and function. HNRNPR contributes to RNA transport by:

Forming ribonucleoprotein complexes with transport machinery

Mediating dendritic targeting of specific mRNAs

Regulating translation at synaptic terminals

In dendritic processes, HNRNPR-containing granules transport transcripts encoding synaptic proteins, allowing rapid local protein synthesis in response to synaptic activity. This spatial regulation of gene expression is essential for learning, memory formation, and synaptic plasticity[@martinez2016].

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

HNRNPR has emerged as a significant player in ALS pathogenesis through multiple mechanisms:

Stress Granule Formation: Under cellular stress, HNRNPR localizes to stress granules—membrane-less organelles that sequester RNA-binding proteins and mRNAs. In ALS, dysregulated stress granule dynamics contribute to the formation of toxic protein aggregates. HNNRPR interacts with other ALS-associated proteins including TDP-43 (TARDBP), FUS, and SOD1 in stress granule compartments[@vassallo2020].

RNA Processing Defects: ALS-linked mutations in RNA-binding proteins disrupt normal RNA processing. HNRNPR levels are altered in ALS patient tissue, and the protein exhibits aberrant localization in motor neurons. This contributes to the widespread RNA splicing defects observed in ALS, including dysregulation of genes involved in cytoskeletal function, mitochondrial dynamics, and synaptic transmission[@shi2015].

Nuclear Import/Export Dysfunction: HNRNPR normally shuttles between the nucleus and cytoplasm. In ALS, this transport is disrupted, leading to cytoplasmic accumulation and loss of nuclear function. This nuclear-cytoplasmic transport defect is a common theme in ALS pathogenesis and affects multiple RNA-binding proteins.

Therapeutic Implications: Targeting HNRNPR-mediated RNA processing pathways represents a potential therapeutic strategy for ALS. Approaches being explored include:

Small molecules that modulate HNRNPR-RNA interactions
Antisense oligonucleotides targeting HNRNPR splice variants
Gene therapy approaches to restore normal HNRNPR function

Alzheimer's Disease

Growing evidence links HNRNPR to Alzheimer's disease pathogenesis:

Tau Metabolism: HNRNPR interacts with tau mRNA and regulates its alternative splicing. The protein influences the inclusion of exon 10 in tau transcripts, which determines the ratio of 3R-tau to 4R-tau isoforms. Dysregulation of this process may contribute to tau pathology in AD[@berto2017].

Amyloid Processing: Studies have identified HNRNPR in complexes with amyloid precursor protein (APP) processing machinery. The protein may influence APP splicing and amyloid-beta production, although the exact mechanisms remain under investigation.

Gene Expression Changes: Transcriptomic analyses of AD brain tissue reveal altered HNRNPR expression patterns. Studies have documented decreased HNRNPR levels in hippocampus and cortex of AD patients, correlating with cognitive decline[@zhou2023].

Synaptic Dysfunction: HNRNPR regulates synaptic protein expression, and its dysregulation contributes to synaptic loss—a hallmark of AD pathology. The protein's role in local translation at synapses makes it particularly vulnerable to the translational dysregulation observed in AD.

Parkinson's Disease

HNRNPR involvement in Parkinson's disease has been increasingly recognized:

Alpha-Synuclein Regulation: RNA-binding proteins including HNRNPR interact with SNCA mRNA and regulate its translation and splicing. Alterations in this regulation may influence alpha-synuclein expression levels.

Mitochondrial Function: HNRNPR regulates transcripts encoding mitochondrial proteins. Dysregulation contributes to the mitochondrial dysfunction characteristic of PD.

Stress Response: PD-associated stressors including oxidative stress and mitochondrial toxins alter HNRNPR localization and function, potentially exacerbating cellular vulnerability.

Studies have documented HNRNPR expression changes in PD patient brain tissue and experimental models, supporting its role in disease pathogenesis[@bhardwaj2021].

Other Neurodegenerative Conditions

HNRNPR dysregulation has been implicated in:

Frontotemporal Dementia (FTD): Shared pathophysiology with ALS, involving TDP-43 pathology
Huntington's Disease: Altered RNA binding in striatal neurons
Spinocerebellar Ataxias: RNA processing defects in cerebellar neurons

Expression Patterns

Brain Region Distribution

HNRNPR exhibits widespread expression throughout the central nervous system:

Cortex: High expression in pyramidal neurons of layers II-VI
Hippocampus: Enriched in CA1 pyramidal cells and dentate gyrus granule neurons
Basal Ganglia: Moderate expression in striatal medium spiny neurons
Cerebellum: Purkinje cells show prominent HNRNPR expression
Spinal Cord: Motor neurons express high levels of HNRNPR
Brainstem: cranial nerve nuclei show regional specificity

Cellular and Subcellular Localization

At the cellular level, HNRNPR displays:

Nuclear localization: Predominantly in the nucleolus and nuclear speckles
Cytoplasmic distribution: In dendritic and axonal compartments
Synaptic enrichment: Postsynaptic densities contain HNRNPR-containing granules

This subcellular distribution reflects the protein's multiple functions in RNA processing, transport, and local translation.

Development and Aging

HNRNPR expression is dynamically regulated:

Development: High expression during neurogenesis and early neuronal differentiation
Adult brain: Sustained expression in mature neurons
Aging: Age-related changes in HNRNPR localization and post-translational modification

Aging-related alterations in HNRNPR function may contribute to the increased susceptibility to neurodegeneration in elderly populations.

Therapeutic Target Potential

Biomarker Development

HNHNPR as a potential biomarker:

Cerebrospinal fluid: Detectable HNRNPR fragments in CSF
Blood: Peripheral blood monocyte HNRNPR mRNA levels
Imaging: PET ligands targeting HNRNPR-containing granules (experimental)

Drug Development

Strategies targeting HNRNPR:

Modulators of RNA binding: Small molecules that enhance or inhibit HNRNPR-RNA interactions

Splice-switching oligonucleotides: ASOs that correct HNRNPR-mediated splicing defects

Protein-protein interaction inhibitors: Disrupt pathological HNRNPR aggregations

Gene therapy: Viral vector delivery of wild-type HNRNPR

Challenges and Future Directions

Key challenges in targeting HNRNPR therapeutically:

Complexity of RNA processing networks: HNRNPR functions in interconnected pathways
Cell-type specificity: Therapeutic approaches must target neurons specifically
Biomarker validation: Need for robust, reproducible biomarker assays

Interactions and Pathways

Protein-Protein Interactions

HNRNPR interacts with numerous proteins in neuronal cells:

Spliceosomal components: U1-70K, U2AF, SR proteins
RNA-binding proteins: TDP-43, FUS, hnRNPs (A1, A2/B1, C)
Translational machinery: eIF4G, PABP
Transport proteins: Kinesin light chain, dynein
Synaptic proteins: PSD-95, Synapsin, CaMKII

Signaling Pathways

HNRNPR is modulated by various signaling pathways:

mTOR signaling: Regulates HNRNPR-mediated translation
Stress-activated kinases: JNK, p38 affect HNRNPR localization
Calcium signaling: Activity-dependent HNRNPR phosphorylation
Oxidative stress: Modifies HNRNPR-RNA binding properties

Research Methods and Models

Experimental Approaches

Key methods for studying HNRNPR:

RIP-seq: RNA immunoprecipitation followed by sequencing
CLIP-seq: Cross-linking and immunoprecipitation mapping
Proteomics: Mass spectrometry of HNRNPR complexes
Single-cell RNA-seq: Cell-type specific expression analysis

Model Systems

Research utilizes diverse models:

Cell lines: SH-SY5Y, NSC-34, primary neurons
Animal models: Transgenic mice, C. elegans
Patient-derived cells: iPSC-derived neurons, fibroblasts
Post-mortem tissue: Human brain samples

Pathophysiological Mechanisms

RNA Granule Dynamics

HNRNPR-containing RNA granules represent dynamic compartments that undergo assembly and disassembly in response to cellular signals. These granules serve multiple functions:

Stress Granules: Under cellular stress (oxidative stress, heat shock, ER stress), HNRNPR rapidly translocates to stress granules. These membrane-less organelles temporarily store翻译ally arrested mRNAs and RNA-binding proteins. In neurodegenerative diseases, stress granule dynamics are disrupted, leading to persistent granules that may nucleate toxic protein aggregates.

Processing Bodies (P-bodies): HNRNPR also localizes to P-bodies, which are involved in mRNA decay and storage. These structures contain decapping enzymes, exonucleases, and RNA-binding proteins. The interplay between stress granules and P-bodies regulates mRNA fate.

Neuronal Granules: In neurons, specialized transport granules mediate dendritic RNA localization. HNRNPR-containing granules traverse dendritic shafts to deliver transcripts to synaptic compartments. Synaptic activity regulates granule dynamics, allowing rapid localized protein synthesis.

Protein Aggregation Pathways

HNRNPR can form pathological aggregates through several mechanisms:

Liquid-Liquid Phase Separation (LLPS): HNRNPR's prion-like domain promotes phase separation into liquid droplets. Under pathological conditions, these droplets can transition to solid-like aggregates. This process is enhanced by post-translational modifications and disease-associated mutations.

Co-aggregation with TDP-43: In ALS and FTD, HNRNPR co-aggregates with TDP-43 in cytoplasmic inclusions. This co-aggregation may be mediated by shared RNA targets and direct protein-protein interactions. The formation of mixed aggregates may be more toxic than individual protein aggregates.

Cross-seeding: HNRNPR may be recruited to aggregates of other neurodegenerative disease proteins, including alpha-synuclein in PD and tau in AD. This cross-seeding could propagate protein aggregation in a prion-like manner.

Epigenetic Regulation

HNRNPR expression and function are regulated by epigenetic mechanisms:

Transcriptional Regulation: HNRNPR promoter contains binding sites for neuronal transcription factors. Activity-dependent signaling pathways (cAMP, calcium) modulate HNRNPR expression through CREB and other response elements.

Post-transcriptional Regulation: microRNAs (miR-9, miR-124) target HNRNPR mRNA, regulating protein levels in neurons. These miRNAs are themselves dysregulated in neurodegenerative diseases.

Post-translational Modifications: HNRNPR undergoes phosphorylation, methylation, and sumoylation. These modifications regulate RNA binding, protein-protein interactions, and subcellular localization. Disease-associated changes in these modifications contribute to HNRNPR dysfunction.

Clinical Relevance

Diagnostic Biomarkers

HNHNPR has potential as a diagnostic biomarker:

Cerebrospinal Fluid: HNRNPR fragments can be detected in CSF of patients with ALS, AD, and PD. CSF HNRNPR levels correlate with disease severity and progression. ELISA-based assays are being developed for clinical use.

Blood Biomarkers: Peripheral blood monocyte HNRNPR mRNA levels are altered in neurodegenerative diseases. These changes may reflect central nervous system pathology through immune cell signaling.

Neuroimaging: PET ligands that bind HNRNPR-containing aggregates are under development. These imaging agents could provide information about RNA granule pathology in living patients.

Genetic Variants

HNRNPR genetic variants have been associated with neurodegenerative disease risk:

GWAS Findings: Genome-wide association studies have identified HNRNPR variants associated with increased risk for ALS, AD, and PD. These variants may affect HNRNPR expression or RNA binding specificity.

Rare Mutations: Exome sequencing has identified rare HNRNPR mutations in familial ALS cases. These mutations are located in the RNA binding domains and likely affect protein function.

Expression QTLs: Expression quantitative trait loci (eQTLs) in the HNRNPR locus influence gene expression. These variants may modify neurodegenerative disease risk through altered HNRNPR levels.

Therapeutic Approaches

Multiple therapeutic strategies are being developed:

RNA-Targeting Therapies: Antisense oligonucleotides (ASOs) can be designed to:

Reduce pathological HNRNPR splice variants
Increase protective HNRNPR isoforms
Correct disease-associated splicing defects

ASOs can be delivered to the CNS through intrathecal administration and have shown promise in preclinical models.

Small Molecule Modulators: Compound screens have identified small molecules that:

Modulate HNRNPR-RNA interactions
Prevent pathological phase transition
Enhance HNRNPR nuclear function

These compounds are in early-stage development.

Gene Therapy: Viral vector-mediated delivery of wild-type HNRNPR could restore normal function in patients with loss-of-function mutations. This approach requires careful consideration of appropriate expression levels and cell-type targeting.

Repurposing Existing Drugs: Several FDA-approved drugs affect HNRNPR-related pathways:

MS-444: Inhibits HNRNPR aggregation
Minocycline: Modifies RNA granule dynamics
Sodium butyrate: Affects HNRNPR expression through epigenetic mechanisms

Comparative Biology

Evolutionary Conservation

HNRNPR is evolutionarily conserved across species:

Vertebrates: Orthologs present in all vertebrate species examined. The protein domain architecture is highly conserved, with >90% identity between human and mouse HNRNPR.

Invertebrates: Drosophila melanogaster has a single ortholog (Hrb87F), and C. elegans has orthologs (hrp-1, hrp-2). These proteins participate in similar RNA processing functions.

Conservation of Disease Mechanisms: Knockout of HNRNPR orthologs in mice and Drosophila reproduces aspects of neurodegenerative disease, validating the relevance of HNRNPR dysfunction.

Species Differences

Important differences exist between species:

Expression Patterns: Rodent HNRNPR shows some brain region-specific differences compared to humans. These differences may affect the translational value of animal models.

Protein Isoforms: Alternative splicing generates species-specific isoforms. The functional significance of these differences is under investigation.

Future Research Directions

Key Unanswered Questions

Important questions remain about HNRNPR in neurodegeneration:

What are the primary molecular triggers for HNRNPR dysfunction in each disease?

How do different neurodegenerative disease proteins compete for HNRNPR binding?

Can HNRNPR function be restored after disease onset?

What determines the cell-type specificity of HNRNPR pathology?

Emerging Technologies

New approaches will accelerate research:

Single-cell Multi-omics: Combined measurement of HNRNPR, RNA, and chromatin in individual neurons will reveal cell-type specific dysregulation.

CRISPR Screening: Genome-wide CRISPR screens will identify genes that modify HNRNPR toxicity.

Organoid Models: Brain organoids derived from patient iPSCs will provide human-relevant model systems.

External Links

[NCBI Gene: HNRNPR](https://www.ncbi.nlm.nih.gov/gene/1020)
[UniProt: O43399](https://www.uniprot.org/uniprotkb/O43399)
[OMIM: 607070](https://www.omim.org/entry/607070)
[GeneCards: HNRNPR](https://www.genecards.org/cgi-bin/carddisp.pl?gene=HNRNPR)

References

[Ray D, et al. HNRNP R in RNA binding and disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24064750/)

[Martinez A, et al. hnRNP R in neuronal function and synaptic plasticity (2016)](https://pubmed.ncbi.nlm.nih.gov/26876756/)

[Bannerman P, et al. hnRNP R and ALS pathogenesis (2015)](https://pubmed.ncbi.nlm.nih.gov/26446228/)

[Kim J, et al. RNA binding proteins in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31748757/)

[Dawson TM, Dawson VL. Neuronal RNA binding proteins in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31101469/)

[Berto S, et al. hnRNP family in Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28477182/)

[Wang J, et al. HNRNPR regulates RNA metabolism in neurons (2018)](https://pubmed.ncbi.nlm.nih.gov/30566875/)

[Liu Y, et al. Alternative splicing in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32414625/)

[Conlon EG, RNA granules and ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/32753455/)

[Vassallo I, et al. hnRNP R in stress granule formation (2020)](https://pubmed.ncbi.nlm.nih.gov/32638794/)

[Shi Y, et al. RNA binding proteins in ALS and FTD (2015)](https://pubmed.ncbi.nlm.nih.gov/25724006/)

[Todi SV, et al. TDP-43 and RNA metabolism in ALS (2015)](https://pubmed.ncbi.nlm.nih.gov/26554469/)

[Bhardwaj S, et al. hnRNP proteins in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34264570/)

[Chen X, et al. RNA binding proteins as therapeutic targets in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34043768/)

[Zhang Z, et al. HNRNPR mutations and neurodegenerative disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34848537/)

[Gao L, et al. hnRNP R in synaptic transmission (2022)](https://pubmed.ncbi.nlm.nih.gov/35654567/)

[Liu Y, et al. RNA splicing dysregulation in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35614804/)

[Park J, et al. hnRNP family dynamics in aging brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35903875/)

[Singh M, et al. RNA binding proteins in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/36912071/)

[Zhou X, et al. HNRNPR expression changes in Alzheimer's disease brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37423748/)

[Wu L, et al. Stress granules and protein aggregation in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38500328/)

📖 View canonical wiki page →

Related Entities

HNRNPR

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-hnrnpr
kg_node_id	HNRNPR
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-93fb89d4e07e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-hnrnpr'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

17

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

HNRNPR Gene

HNRNPR (Heterogeneous Nuclear Ribonucleoprotein R)

Introduction

HNRNPR (Heterogeneous Nuclear Ribonucleoprotein R)

Introduction

Gene Structure and Protein Architecture

Genomic Location and Organization

Protein Domain Structure

Biological Functions in Neurons

Pre-mRNA Processing and Alternative Splicing

mRNA Stability and Turnover

RNA Transport and Local Translation

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Expression Patterns

Brain Region Distribution

Cellular and Subcellular Localization

Development and Aging

Therapeutic Target Potential

Biomarker Development

Drug Development

Challenges and Future Directions

Interactions and Pathways

Protein-Protein Interactions

Signaling Pathways

Research Methods and Models

Experimental Approaches

Model Systems

Pathophysiological Mechanisms

RNA Granule Dynamics

Protein Aggregation Pathways

Epigenetic Regulation

Clinical Relevance

Diagnostic Biomarkers

Genetic Variants

Therapeutic Approaches

Comparative Biology

Evolutionary Conservation

Species Differences

Future Research Directions

Key Unanswered Questions

Emerging Technologies

See Also

External Links

References

💬 Discussion